vanishing bile duct syndrome

DEFINITION: A heterogeneous group of acquired (and some congenital) disorders with progressive loss of intrahepatic bile ducts, producing chronic cholestasis. Histologic hallmark = ductopenia: interlobular bile ducts absent in >50% of portal tracts (in a biopsy with at least 10-20 portal tracts). Normally, every hepatic artery branch in the portal tract is accompanied by a bile duct; an artery without its companion duct suggests ductopenia.

PATHOPHYSIOLOGY: Immune-mediated injury (T-cell attack on cholangiocytes), ischemic injury (especially in chronic rejection with obliterative arteriopathy), or direct toxic injury to biliary epithelium. Bile duct epithelium is damaged, ducts are lost faster than they regenerate, and cholestasis follows, which can progress to fibrosis and biliary cirrhosis. Bile acid retention causes further hepatocyte injury.

CAUSES: - Autoimmune/immune-mediated: primary biliary cholangitis (PBC; florid duct lesion, anti-mitochondrial antibodies, middle-aged women), primary sclerosing cholangitis (PSC; "onion-skin" periductal fibrosis, p-ANCA, associated with ulcerative colitis, "beading" on cholangiography), autoimmune hepatitis overlap, sarcoidosis. - Transplant-related: chronic liver allograft rejection (ductopenia plus foam cell arteriopathy), graft-versus-host disease after hematopoietic stem cell transplantation. - Drugs: amoxicillin-clavulanate (most common cause of drug-induced cholestatic injury), chlorpromazine, carbamazepine, flucloxacillin, macrolides, TMP-SMX, ACE inhibitors, terbinafine, and others. Stevens-Johnson syndrome/TEN can also be involved. - Infections: CMV, congenital syphilis, HIV-related cholangiopathy, and other infections. - Malignancy: Hodgkin lymphoma (paraneoplastic), occasionally other lymphomas. - Ischemic: hepatic artery thrombosis, vasculitis. - Congenital/genetic: Alagille syndrome (JAG1 mutation, paucity of interlobular bile ducts, with butterfly vertebrae, posterior embryotoxon, pulmonic stenosis/peripheral pulmonary stenosis, and characteristic facies), nonsyndromic paucity of bile ducts, cystic fibrosis.

CLINICAL FEATURES: Jaundice, pruritus, fatigue, steatorrhea and fat-soluble vitamin (A, D, E, K) deficiency, xanthomas/xanthelasma from hypercholesterolemia, hepatomegaly. Late disease: cirrhosis, portal hypertension, liver failure.

DIAGNOSIS: Cholestatic labs: markedly elevated alkaline phosphatase and GGT, with conjugated hyperbilirubinemia and variable mild transaminase elevation. Rule out extrahepatic obstruction with ultrasound/MRCP. Liver biopsy confirms ductopenia. Work-up by etiology: AMA (PBC), MRCP (PSC), drug history, transplant/HSCT history, and imaging or lymph node evaluation for lymphoma.

MANAGEMENT: Treat or remove the underlying cause (stop the offending drug, treat the infection or lymphoma, increase immunosuppression for rejection or GVHD). Ursodeoxycholic acid is first-line for PBC and is often used for symptomatic cholestasis. Obeticholic acid or fibrates can be used in PBC non-responders. Pruritus: cholestyramine first-line, then rifampin, naltrexone, sertraline. Supplement fat-soluble vitamins. Liver transplantation for end-stage disease. Prognosis depends on cause: drug-induced cases may resolve completely, whereas others (e.g., chronic rejection, severe cases) progress to cirrhosis.

HIGH-YIELD BOARD PEARLS: - Ductopenia = loss of >50% of interlobular bile ducts. - Think PBC (AMA, florid duct lesions with granulomas, lymphocytic infiltrate) and PSC (p-ANCA, onion-skin fibrosis, UC association, cholangiocarcinoma risk) in classic vignettes. - Chronic liver transplant rejection and GVHD are classic causes of ductopenia in post-transplant patients. - Amoxicillin-clavulanate is the classic drug cause. - Alagille syndrome is the classic pediatric cause (JAG1, Notch pathway). - Pattern of injury is cholestatic (↑ ALP, ↑ GGT, ↑ conjugated bilirubin).